StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Trimetazidin

Trimetazidine

HCID 21109
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
5011-34-7
Standard-SMILES
COc1ccc(CN2CCNCC2)c(OC)c1OC
InChIKey
UHWVSEOVJBQKBE-UHFFFAOYSA-N
Summenformel
C14H22N2O3
Durchschnittliche Molmasse
266,34 g/mol
Monoisotopische Masse
266,16304257

Überblick

1-[(2,3,4-trimethoxyphenyl)methyl]piperazine is an aromatic amine.

Namen und Bezeichner

Bevorzugter Name
Trimetazidine
IUPAC
1-[(2,3,4-trimethoxyphenyl)methyl]piperazine
Lokaler Name
Trimetazidin
Englischer Name
Trimetazidine
Summenformel
C14H22N2O3
Molmasse
266.34

Namen und Synonyme

TRIMETAZIDINE5011-34-71-[(2,3,4-trimethoxyphenyl)methyl]piperazineTrimetazidinaTrimetazidinumDilatanN9A0A0R9S8Piperazine, 1-((2,3,4-trimethoxyphenyl)methyl)-DTXSID2048531Piperazine, 1-[(2,3,4-trimethoxyphenyl)methyl]-1-((2,3,4-trimethoxyphenyl)methyl)piperazineVastarel MR
Weitere Namen anzeigen
TRIMETAZIDINE HCLVasorelVasartelAKOS B006602TIMTEC-BB SBB007020ART-CHEM-BB B006602ART-CHEM-BB B014361Trimetazidine USP/EP/BP
RefChem:191732DTXCID9027998C01EB15225-690-21-(2,3,4-Trimethoxybenzyl)piperazineMFCD008682631-(2,3,4-Trimethoxy-benzyl)-piperazinePreductal

Datenbank-Bezeichner

CAS
5011-34-7
PubChem CID
21109
DTXSID
DTXSID2048531
ChEMBL
CHEMBL203266
ChEBI

Eigenschaften

Berechnete Struktureigenschaften

XLogP
1
Polarare Oberfläche (TPSA)
43 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
5
Frei drehbare Bindungen
5
Schwere Atome
19
Formalladung
0
Komplexität
259

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

Pharmaceuticals -> Listed in ZINC15

LogP1.04
Dissociation ConstantspKa1= 4.45 ± 0.02 and pKa2= 9.14 ± 0.02

Physikochemische Eigenschaften

Siedepunkt
2 · bp2 200-205°
Dichte
1.092 · 1.092±0.06 g/cm3(Predicted)
Dampfdruck
0.003 Pa · 0.003Pa at 25℃
storage temp.
Hygroscopic, Refrigerator, Under inert atmosphere
Löslichkeit
Chlorofrom (Slightly), Methanol (Slightly)
Aggregatzustand
Solid
pka
9.07 · 9.07±0.10(Predicted)
Farbe
Colourless to Pale Yellow Gel
Stabilität
Hygroscopic

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H226 (66.7%): Flammable liquid and vapor [Warning Flammable liquids]

P210, P233, P240, P241, P242, P243, P260, P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P301+P330+P331, P302+P352, P302+P361+P354, P303+P361+P353, P304+P340, P305+P351+P338, P305+P354+P338, P316, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P363, P370+P378, P403+P233, P403+P235, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 3 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory InformationREACH registered substance: Trimetazidine (EC: 225-690-2)
Hazard Classes and CategoriesFlam. Liq. 3 (66.7%)

Toxikologische Informationen

Drug Induced Liver Injury · 4 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Trimetazidine

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Sicherheitsdaten

hazard_code
Xi
hazard_class
IRRITANT

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

C01EB15

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingTrimetazidine is 15% protein bound in plasma. Trimetazidine can bind to human serum albumin.
Pharmacodynamics · 1 Eintrag

Trimetazidine is indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies. Patients should be counselled regarding the risk of use with reduced renal or hepatic function, worsening of extrapyramidal symptoms or other movement disorders, and risk of falls.

Mechanism of Action · 1 Eintrag

During myocardial ischemia, anaerobic metabolism takes over, increasing levels of lactic acid. The decreased intracellular pH and increased concentration of protons activates sodium-hydrogen and sodium-calcium antiport systems, raising intracellular calcium concentrations, finally leading to decreased contractility. This injury to the myocardium raises concentrations of catecholamines, which activate hormone sensitive lipase, and increasing fatty acid concentrations in plasma. When the myocardium is repurfused, fatty acid oxidation becomes the dominant form of ATP production, maintaining an acidic pH, and further exacerbating the injury. The mechanism of action of trimetazidine is not fully understood. Trimetazidine may inhibit mitochondrial 3-ketoacyl coenzyme A thiolase, decreasing long chain fatty acid β-oxidation but not glycolysis in the myocardium. The decreased long chain fatty acid β-oxidation is compensated for by increased use of glucose, preventing a lowered myocardial pH, and further decreases in contractility. However, another study suggests that 3-ketoacyl coenzyme A thiolase may not be trimetazidine's target, and that this mechanism may be incorrect.

Biological Half-LifeIn young, healthy subjects, the half life of trimetazidine is 7.81 hours. In patients over 65, the half life increases to 11.7 hours.
Metabolism/Metabolites · 1 Eintrag

Zugehörige Reaktionen

14
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 22261
HRID 22261als Edukt
Reaktionsgleichung von HRID 37177
HRID 37177als Edukt
Reaktionsgleichung von HRID 37178
HRID 37178als Edukt
Reaktionsgleichung von HRID 298576
HRID 298576als Edukt
Reaktionsgleichung von HRID 307602
HRID 307602als Edukt
Reaktionsgleichung von HRID 568735
HRID 568735als Edukt
Reaktionsgleichung von HRID 694702
HRID 694702als Edukt
Reaktionsgleichung von HRID 945736
HRID 945736als Edukt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
CHEBI:94789
UNII
N9A0A0R9S8
EC Number
225-690-2
Nikkaji
J8.797A
LogP
1.143 at · 1.143 at 25℃ and pH6
CAS Datenbank
5011 · 5011-34-7(CAS DataBase Reference)

Trimetazidine can be oxidized at the piperazine ring to form trimetazidine ketopiperazine. Trimetazidine can also be N-formylated, N-acetylated, or N-methylated at the piperazine ring to form N-formyltrimetazidine, N-acetyltrimetazidine, and N-methyltrimetazidine respectively. Alternatively, trimetazidine can be demethylated at the 2, 3, or 4 position of the 2,3,4-trimethoxybenzyl moiety to form 2-desmethyltrimetazidine, 3-desmethyltrimetazidine, or 4-desmethyltrimetazidine. The desmethyltrimetazidine metabolites can undergo sulfate conjugation or glucuronidation prior to elimination.

MeSH Pharmacological ClassificationDrugs used to cause dilation of the blood vessels.
Absorption, Distribution and Excretion · 4 Einträge

In elderly patients, a 35 mg oral modified release tablet reaches a mean Cmax of 115 µg/L, with a Tmax of 2.0-5.0 hours, and a mean AUC0-12 of 1104 h\*µg/L. In young, healthy patients, the same dose reaches a mean Cmax of 91.2 µg/L, with a Tmax of 2.0-6.0 hours, and an AUC0-12h 720 h\*µg/L.

Trimetazidine is 79-84% eliminated in the urine, with 60% as the unchanged parent compound. In a study of 4 healthy subjects, individual metabolites made up 0.01-1.4% of the dose recovered in urine. In the urine, 2-desmethyltrimetazidine made up 0-1.4% of the recovered dose, 3- and 4-desmethyltrimetazidine made up 0.039-0.071% each, N-methyltrimetazidine made up 0.015-0.11%, trimetazidine ketopiperazine made up 0.011-0.4%, N-formyltrimetazidine made up 0.035-0.42%, N-acetyltrimetazidine made up 0.016-0.19%, desmethyl trimetazidine O-sulphate made up 0.01-0.65%, and an unknown metabolite made up0.026-0.67%.

The volume of distribution of trimetazidine is 4.8 L/kg.

Trimetazidine clearance is strongly correlated with creatinine clearance. In eldery patients with a creatinine clearance of 72 ± 8 mL/min, trimetazidine clearance was 15.69 L/h. In young, healthy patients with a creatinine clearance of 134 ± 18 mL/min, trimetazidine clearance was 25.2 L/h.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

NatriumcarbonatPiperazin-1-carbaldehyd2,3,4-Trimethoxybenzyl chloride4-[(2,3,4-TriMethoxyphenyl)Methyl]-1-piperazinecarboxylic Acid Ethyl Ester1-Chloromethyl-2,3,4-trimethoxybenzene2,3,4-Trimethoxybenzaldehyd1-BOC-Piperazine

Nachgelagerte Produkte

Lomerizine hydrochloride